NCKL:IDXPT Trimegah Bangun Persada Tbk Analysis
Data as of 2026-06-19 - not real-time
IDR 910.00
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
The stock is trading below its 20‑day, 50‑day and 200‑day simple moving averages, signaling a bearish bias. RSI hovers around the neutral zone and the MACD line remains negative while the histogram is positive, suggesting tentative bullish momentum but no decisive trend reversal. Volume is on a decreasing path and 30‑day volatility is elevated, indicating heightened price swings, yet beta is near zero, implying minimal systematic market risk.
Fundamentally, the price‑to‑earnings multiple is well below market norms and the DCF model hints the market price may sit modestly above intrinsic value. Revenue is contracting, though margins stay solid; however, the debt‑to‑equity ratio is exceptionally high, raising balance‑sheet concerns. The company does not distribute dividends, limiting appeal for income‑focused investors. Analyst consensus skews strongly bullish with a sizable upside potential, creating a nuanced picture: short‑term technical weakness against medium‑term valuation attractiveness.
Fundamentally, the price‑to‑earnings multiple is well below market norms and the DCF model hints the market price may sit modestly above intrinsic value. Revenue is contracting, though margins stay solid; however, the debt‑to‑equity ratio is exceptionally high, raising balance‑sheet concerns. The company does not distribute dividends, limiting appeal for income‑focused investors. Analyst consensus skews strongly bullish with a sizable upside potential, creating a nuanced picture: short‑term technical weakness against medium‑term valuation attractiveness.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- price below key moving averages
- decreasing volume and high short‑term volatility
- neutral RSI with marginal bullish MACD histogram
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- low P/E and attractive valuation relative to peers
- strong profit margins and solid ROE
- significant upside potential indicated by analyst targets
Long Term
> 3 yearsNeutral
Model confidence: 5/10
Key Factors
- high debt‑to‑equity ratio creating balance‑sheet risk
- stable operating cash flow supporting continuity
- absence of dividend limiting total return profile
Key Metrics & Analysis
Financial Health
Revenue Growth-4.50%
Profit Margin34.13%
P/E Ratio5.7
ROE25.96%
ROA8.05%
Debt/Equity18.03
P/B Ratio1.4
Op. Cash FlowIDR7247.2B
Free Cash FlowIDR4256.4B
Technical Analysis
TrendBearish
RSI50.5
SupportIDR 735.00
ResistanceIDR 970.00
MA 20IDR 854.50
MA 50IDR 989.10
MA 200IDR 1,139.60
MACDBullish
VolumeDecreasing
Fear & Greed Index92.14
Valuation
Fair ValueIDR 833.24
Target PriceIDR 1,575.33
Upside/Downside73.11%
GradeFair
TypeValue
Risk Assessment
Beta0.02
Volatility79.71%
Sector RiskHigh
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.